Mr. Kym Anthony reports
AVIVAGEN ANNOUNCES SALES OF COMPANION ANIMAL PRODUCT AND MANAGEMENT CHANGE
Avivagen Inc. had significant new and expanded sales of the company's companion animal products. The new sales include a 1,500-unit order for Vivamune from an existing distribution partner in Taiwan, as well as two new customer wins in Mexico.
The 1,500-unit order represents the largest single order from Avivagen's Taiwan-based distribution partner this year and reflects increased consumer awareness and interest for Vivamune in Taiwan. OxC-beta complex is also used as a key ingredient by a leading producer of premium dog food in Taiwan, as the company recently expanded its product line of dog food containing OxC-beta to include canned food in addition to its dry kibble product.
The first of two new customers in Mexico, an independent distributor of high-quality nutritional products for dogs, has ordered 4,000 units of white labelled product which it will market under its own brand. The second Mexican customer has placed an initial order for 500 units of Vivamune, which follows its own successful internal study and which it plans to market through veterinary clinics and hospitals.
"We are seeing great interest and opportunity for Avivagen in the companion animal market today. These new sales and customer wins in key markets like Taiwan and Mexico follow sales in Canada and the U.S., and are clear signs of the growing demand for our companion animal product as an important part of promoting pet health," says Kym Anthony, chief executive officer of Avivagen. "We are excited to be expanding our customer base and recurring business in these areas."
Avivagen also today announced the departure of Chris Boland as chief financial officer. The company expects to announce a new leader for its financial functions in the near term.
"We thank Chris for his efforts and dedication to Avivagen and look forward to announcing a new financial leader to support the next phase of our growth around the globe," adds Mr. Anthony.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.